帮我润色这段学术论文Along with SERD research a number of problems have been revealed For example the acrylic groups often used in early SERD had a greater side effect on the uterus 5 6 and cause greater toxicit

With the progress of research on selective estrogen receptor degraders (SERD), several issues have come to light. For instance, the use of acrylic groups in early SERD has been shown to have adverse effects on the uterus and cause toxicity to patients. Additionally, the clinical benefits of SERD against drug resistance issues and ESR1 mutations are limited to a narrow patient population, making it difficult to establish clear clinical superiority. Moreover, the available Fulvestrant can only be administered through intramuscular injection, and its absorption rate is lower than that of oral drugs. Hence, developing more potent and safe SERD with a broader clinical benefit has become a primary focus of research. To address the issue of drug resistance, scientists have proposed the concept of selective estrogen receptor co-antagonists (SERCA), which uses the mutant hotspot amino acid residue C530 as a covalent target. The SERCA drug H3B-6545 is currently in clinical phase II. This review outlines the optimization pathways of selective estrogen receptor degraders and newly synthesized derivatives, and their current development status. We also classify SERD according to their parent nucleus and propose emerging solutions such as SERCA to address problems like drug resistance. Finally, we describe the current development status and optimization ideas for SERD and SERCA, and hope to provide new directions for their optimization and the treatment of ER-related diseases